NewsMeter

Tectonic Reports Favorable TX2100 Phase 1a Data, Gains FDA Fast Track

9/30/2026

(NASDAQ: TECX) reported that single ascending doses of TX2100 were generally safe and well-tolerated in a Phase 1a clinical trial.

Food and Drug Administration granted Fast Track designation to TX2100 for Hereditary Hemorrhagic Telangiectasia (HHT) and cleared the Investigational New Drug application for the next phase of trials.

The Phase 1a trial evaluated 48 healthy adult volunteers. The company reported that the drug was generally safe and well-tolerated across all six planned dose cohorts.

Treatment-emergent adverse events were mild or moderate and transient. There were no deaths, serious adverse events, or severe treatment-emergent adverse events at any dose level.